Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

Sherif S. Farag, Shuhong Zhang, Buffy S. Jansak, Xiaojing Wang, Eric Kraut, Kenneth Chan, Janet E. Dancey, Michael R. Grever

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25 mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fatigue (n = 3), neutropenia (n = 2), thrombocytopenia (n = 2), interstitial pneumonitis (n = 1), stomatitis (n = 1) and diarrhea (n = 1). Clinical activity was associated with a higher area under the curve (AUC) and maximal reduction in phosphorylated p70S6K and 4EBP1 in peripheral blood mononuclear cells. At the dose and schedule used, temsirolimus had low single agent activity. Investigation of alternate dosing schedules and use in combinations is indicated.

Original languageEnglish (US)
Pages (from-to)1475-1480
Number of pages6
JournalLeukemia Research
Volume33
Issue number11
DOIs
StatePublished - Nov 2009

Keywords

  • mTOR
  • Multiple myeloma
  • Pharmacokinetics
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this